Cardiorenal outcomes and mortality with GLP-1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta-analysis

João Sérgio Neves^{1

2}, Catarina Vale^{1

3}, Ana Rita Leite^{1

2}, João Pedro Ferreira^{1

4}

Affiliations

¹ RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal.
² Department of Endocrinology, Diabetes and Metabolism, ULS São João, Porto, Portugal.
³ Department of Internal Medicine, ULS São João, Porto, Portugal.
⁴ Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

João Sérgio Neves et al. Diabetes Obes Metab. 2025 Oct.

. 2025 Oct;27(10):6032-6038.

doi: 10.1111/dom.16603. Epub 2025 Jul 14.

João Sérgio Neves^{1

2}, Catarina Vale^{1

3}, Ana Rita Leite^{1

2}, João Pedro Ferreira^{1

4}

¹ RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal.
² Department of Endocrinology, Diabetes and Metabolism, ULS São João, Porto, Portugal.
³ Department of Internal Medicine, ULS São João, Porto, Portugal.
⁴ Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

No abstract available

Keywords: GLP‐1 receptor agonist; SGLT2 inhibitor; cardiovascular outcomes; kidney outcomes; type 2 diabetes.

References

1. ADA. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes‐2025. Diabetes Care. 2025;48:S181‐s206. doi:10.2337/dc25‐S009
1. Badve SV, Bilal A, Lee MMY, et al. Effects of GLP‐1 receptor agonists on kidney and cardiovascular disease outcomes: a meta‐analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13:15‐28. doi:10.1016/s2213‐8587(24)00271‐7
1. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta‐analysis. JAMA Cardiol. 2021;6:148‐158. doi:10.1001/jamacardio.2020.4511
1. Neves JS, Borges‐Canha M, Vasques‐Nóvoa F, et al. GLP‐1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes. J Am Coll Cardiol. 2023;82:517‐525. doi:10.1016/j.jacc.2023.05.048
1. Neuen BL, Fletcher RA, Heath L, et al. Cardiovascular, kidney, and safety outcomes with GLP‐1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta‐analysis. Circulation. 2024;150:1781‐1790. doi:10.1161/circulationaha.124.071689